Direct-acting antivirals that target different steps of the hepatitis C virus (HCV) lifecycle offer the prospect of shorter treatment, fewer side-effects and higher cure rates for people with HIV and HCV co-infection as well as people with HCV mono-infection. An oral regimen of three direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people with both HIV and genotype 1 hepatitis C co-infection in the TURQUOISE-I study, presented at AIDS 2014.

View the full post here.